We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesQuantum BioPharma Ltd Ordinary Shares - Class B (Sub Voting)

Quantum BioPharma Ltd Ordinary Shares - Class B (Sub Voting)

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None CAD 0.00(0%)
Last update at 2026-11-12T17:10:03.787521Z
Market Cap
27.40M

Momentum Score

…

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. It operates through two segments, Biopharmaceutical Innovation and Strategic Investments. The company researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is headquartered in Toronto, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
2.85
Low
52.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Quantum BioPharma Ltd (QNTM.CN) is a publicly listed company; publicly available disclosures about its business, products and strategy are limited, preventing a detailed description. Long-term growth drivers are unclear from public filings, and investors may find potential upside only if the company discloses credible product, clinical, regulatory or commercial progress and executes financing or partnership strategies.
Key risks include limited operating history, likely need for additional capital with attendant dilution, low liquidity and resulting share-price volatility.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-346.87%
Net Debt
-
ROCE
-300.19%
Diluted EPS TTM
-12.65

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -26.96M -14.92M -18.23M -26.70M -33.94M
Minority interest 0.78M 0.71M 0.33M 0.00M -
Net income -26.18M -14.20M -17.90M -23.61M -35.29M
Selling general administrative 12.01M 9.31M 13.20M 15.98M 23.37M
Reconciled depreciation 0.55M 0.49M 2.51M 4.53M -
Operating income -15.32M -15.88M -19.57M -27.43M -33.74M
Interest expense 0.62M 0.05M 0.00M 0.05M -
Interest income 0.24M 0.57M 0.79M 0.37M 0.20M
Net interest income -0.38M 0.53M 0.79M 0.32M -
Extraordinary items - - - - -1.35M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 15.32M 15.88M 19.57M 27.43M -
Total other income expense net -11.26M 0.44M 0.55M 0.41M -
Net income from continuing ops -26.96M -14.92M -18.23M -26.70M -
Net income applicable to common shares - - - - -35.29M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 11.16M 17.12M 17.47M 38.41M 62.96M
Intangible assets 4.51M 4.93M 5.36M 12.04M 16.20M
Other current assets 2.21M 0.86M - 0.00M 8.65M
Total liab 6.06M 6.68M 4.57M 7.87M 8.83M
Total stockholder equity 6.92M 11.48M 13.24M 30.54M 54.13M
Other current liab - 0.49M 0.03M - -
Common stock - - - 143.41M 152.32M
Capital stock 169.70M 150.47M 137.78M - -
Retained earnings -198.29M -172.11M -157.91M -142.02M -121.02M
Cash 1.91M 6.00M 2.76M 16.98M 35.26M
Total current liabilities 6.06M 6.68M 4.57M 7.83M 8.70M
Short term debt - - - 0.30M 0.30M
Short long term debt 1.77M 0.77M 0.30M - -
Other stockholder equity - - - 0.65M 0.24M
Property plant equipment - - - 0.26M 0.17M
Total current assets 6.48M 12.05M 11.09M 17.85M 45.93M
Long term investments 0.00M 0.00M 0.01M - -
Short term investments 0.46M 1.20M 0.76M 0.02M 0.16M
Net receivables - - - 0.10M 0.23M
Inventory 0.05M 0.12M 0.00M - -
Accounts payable 1.98M 3.25M 3.24M - -
Non current assets total 4.68M 5.07M 6.39M - -
Capital lease obligations 0.10M 0.05M 0.04M - -
Long term debt total - - - 0.04M 0.13M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -1.95M - - - 0.00M
Total cashflows from investing activities - -1.50M -0.27M 12.12M -
Net borrowings 5.24M - - - -0.13M
Total cash from financing activities 6.10M 11.62M -3.13M -2.07M 38.21M
Net income -26.18M -14.92M -18.23M -26.70M -35.29M
Change in cash -4.09M 3.24M -14.22M -18.28M 17.73M
Begin period cash flow 6.00M - - - 17.52M
End period cash flow 1.91M - - - 35.26M
Total cash from operating activities -8.24M -6.88M -10.83M -28.33M -20.75M
Issuance of capital stock 0.34M - - - 38.34M
Depreciation 0.55M 0.49M 2.51M 4.53M 4.05M
Other cashflows from investing activities - -1.50M -0.27M 12.49M -
Change to inventory 0.07M - - - -
Sale purchase of stock 0.00M 10.67M -2.94M -1.93M 0.00M
Other cashflows from financing activities - - - 0.00M -
Capital expenditures 0.00M 0.00M 0.00M 0.36M 0.50M
Change in working capital 1.99M 8.76M 1.64M -7.12M 2.89M
Stock based compensation 2.95M - - - 7.44M
Other non cash items 2.13M - - - 0.02M
Free cash flow -8.24M - - - -21.25M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
DRUG
Bright Minds Biosciences Inc		 0.06
0.19%		 32.18 - - - 13.50 - -0.10
METX
ME Therapeutics Holdings Inc.		 -
-%		 1.05 - - - 72.00 - -
TELI
Telescope Innovations Corp.		 -
-%		 0.34 - - 4.32 6.45 4.32 -1.62
DTC
Defence Therapeutics Inc		 -
-%		 0.31 - - - 89.80 - -9.99

Profile*

Quantum BioPharma Ltd Ordinary Shares - Class B (Sub Voting)

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. It operates through two segments, Biopharmaceutical Innovation and Strategic Investments. The company researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is headquartered in Toronto, Canada.

55 University Avenue, Toronto, ON, Canada, M5J 2H7

833 571 1811

https://www.quantumbiopharma.com

Name Title Year Born
Mr. Zeeshan Saeed Co-Founder, CEO, & Executive Non-Independent Co-Chairman 1970
Mr. Anthony John Durkacz Co-Founder & Executive Non-Independent Co-Chairman 1976
Mr. Donal Carroll CPA Chief Financial Officer 1977
Mr. Nathan Coyle CPA Controller 1981
Dr. Lakshmi P. Kotra BPHARM, Ph.D. CEO of Lucid & Director 1971
Dr. Andrzej Chruscinski M.D., Ph.D. Vice President of Clinical & Scientific Affairs NA
Dr. Ashwini Joshi Director of Pharmaceutical Development NA
Mr. Jason David Sawyer Head of Finance & Mergers and Acquisitions 1972
Ms. Maryann Adesso Corporate Secretary NA
Randell Mack President of FSD BioSciences NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…